Human Molecular Genetics, 2003, Vol. 12, No. 13 1621-1629
DOI: 10.1093/hmg/ddg163
© 2003 Oxford University Press
Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context
1Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA, 2Department of Neurology, University of Michigan, Ann Arbor, MI 48109-0585, USA, 3Geriatrics Research, Education, and Clinical Center, Ann Arbor VAMC, Ann Arbor, MI 48109, USA and 4Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Received March 24, 2003; Accepted April 28, 2003
In order to better understand the role of nuclear localization of polyglutamine in the human CAG repeat disorders, gene targeting was used to add either nuclear localization (NLS) or nuclear export (NES) signals to versions of the mouse Hprt protein containing expanded polyglutamine (HprtQ150). The NLS increased levels of nuclear HprtQ150 protein in the mouse brain and hastened both the presentation of neuronal intranuclear inclusions (NIIs) and the onset of behavioral abnormalities. The NES reduced levels of nuclear HprtQ150 protein in mouse brain and delayed both the presentation of NIIs and the onset of behavioral abnormalities. Together these results indicate the nucleus is the primary site of toxicity in HprtQ150 mice. Furthermore, the signals did not alter the relative regional distribution of NIIs, suggesting that factors other than nuclear access dictate the regional specificity of NII formation in this mouse model.
* To whom correspondence should be addressed. Email: pdetloff{at}bmg.bhs.uab.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C.-E. Wang, H. Zhou, J. R. McGuire, V. Cerullo, B. Lee, S.-H. Li, and X.-J. Li Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin J. Cell Biol., May 28, 2008; 181(5): 803 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Van Raamsdonk, Z. Murphy, E. J. Slow, B. R. Leavitt, and M. R. Hayden Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease Hum. Mol. Genet., December 15, 2005; 14(24): 3823 - 3835. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Benn, C. Landles, H. Li, A. D. Strand, B. Woodman, K. Sathasivam, S.-H. Li, S. Ghazi-Noori, E. Hockly, S. M.N.N. Faruque, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet., October 15, 2005; 14(20): 3065 - 3078. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schilling, A. V. Savonenko, A. Klevytska, J. L. Morton, S. M. Tucker, M. Poirier, A. Gale, N. Chan, V. Gonzales, H. H. Slunt, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice Hum. Mol. Genet., August 1, 2004; 13(15): 1599 - 1610. [Abstract] [Full Text] [PDF] |
||||

